# OnCo record aml-paediatric (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/aml-paediatric/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "aml-paediatric" ;
  schema:name "Acute myeloid leukaemia in children"@en ;
  schema:alternateName "Childhood AML"@en, "Paediatric AML"@en, "Pediatric acute myeloid leukemia"@en ;
  schema:description "Acute myeloid leukaemia in children carries gene fusions rather than the mutations of ageing, is treated with four or five intensive courses of chemotherapy, and cures around two thirds of children. Adding gemtuzumab ozogamicin lowered relapse in the AAML0531 trial, and the menin inhibitor revumenib is the first targeted drug approved for the KMT2A-rearranged form common in young children."@en ;
  schema:url <https://onco.cc/cancers/aml-paediatric/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acute_myeloid_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Acute_myeloid_leukemia>, <https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/aml-npm1-kmt2a/>, <https://onco.cc/cancers/aml-flt3/>, <https://onco.cc/cancers/apl/>, <https://onco.cc/cancers/all-infant/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/cardio-oncology/> ;
  onco:targets <https://onco.cc/targets/cd33/>, <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/kmt2a/>, <https://onco.cc/targets/menin/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/institutions/st-jude/> ;
  onco:pathways <https://onco.cc/pathways/menin-kmt2a/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/secondary-malignancy/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-aaml0531-gemtuzumab-gamis-jco-2014/>, <https://onco.cc/key-papers/paper-aaml1031-sorafenib-flt3-pollard-jco-2022/>, <https://onco.cc/key-papers/paper-bolouri-paediatric-aml-genomics-nat-med-2018/> ;
  onco:pipeline <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/technologies/menin-inhibitors/>, <https://onco.cc/drugs/dexrazoxane/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/drugs/cpx-351/> ;
  onco:standardOfCare <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/daunorubicin/>, <https://onco.cc/drugs/mitoxantrone/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/gemtuzumab-ozogamicin/>, <https://onco.cc/trials/aaml0531/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/mitoxantrone/>, <https://onco.cc/drugs/gemtuzumab-ozogamicin/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/targets/flt3/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/drugs/fludarabine/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/trials/augment-101/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/dexrazoxane/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/transfusion-support/> .